Key Points
- COO Kathleen Goin sold 4,302 shares on March 18 at an average of $117.99 for $507,592.98 (she previously sold 4,302 shares on Jan 21 at $97.63 for $420,004.26); the transactions were disclosed in an SEC filing.
- Palvella shares opened at $112.50, with a 50-day moving average of $103.11, a 200-day moving average of $88.18, a market cap of about $1.33 billion, and a 1‑year range of $18.23–$151.18.
- Analysts are broadly positive, giving an average rating of "Buy" and an average target price of $184.87, with individual targets up to $250 (two Strong Buy, 13 Buy, one Sell).
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the firm's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, January 21st, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26.
Palvella Therapeutics Trading Down 1.2%
Shares of NASDAQ PVLA opened at $112.50 on Friday. The company has a fifty day moving average price of $103.11 and a 200 day moving average price of $88.18. The firm has a market cap of $1.33 billion, a PE ratio of -42.78 and a beta of -0.30. Palvella Therapeutics, Inc. has a 1-year low of $18.23 and a 1-year high of $151.18.
Hedge Funds Weigh In On Palvella Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Archer Investment Corp bought a new stake in Palvella Therapeutics during the third quarter worth $28,000. Group One Trading LLC increased its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company's stock worth $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics in the 2nd quarter valued at about $37,000. Finally, JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares during the period. 40.11% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on PVLA. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Weiss Ratings reissued a "sell (d)" rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. Chardan Capital restated a "buy" rating and set a $210.00 target price on shares of Palvella Therapeutics in a report on Monday, March 16th. Craig Hallum began coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They issued a "buy" rating and a $175.00 target price for the company. Finally, Mizuho raised their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Palvella Therapeutics presently has an average rating of "Buy" and an average target price of $184.87.
Check Out Our Latest Research Report on PVLA
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
